Starget Pharma Raises $18M Series A to Accelerate AI-Powered Radioligand Cancer Therapies and US Expansion

Israeli clinical-stage biotech Starget Pharma has secured an $18 million Series A funding round to propel its innovative cancer treatments forward.

The round was led by Ilex Medical Ltd, with key participation from Louisiana Growth Fund, Cancer Focus Fund, BRF, and other investors, bringing total funding to $38 million since 2019.

AI-Driven Precision Oncology Revolution

Starget Pharma's proprietary AI-driven platform designs Smart Targeted Radioligands (STRs) that combine diagnostic imaging and therapeutic isotopes for targeted cancer treatment.

The lead program, a first-in-class SSTR3-targeted theranostic pair, addresses sarcoma, neuroendocrine tumors, and malignant melanoma with minimal damage to healthy tissue.

Key Collaborations Fueling Growth

A strategic partnership with the Center for Molecular Imaging and Therapy (CMIT) in Shreveport, Louisiana, provides end-to-end infrastructure for preclinical and clinical development.

Additionally, collaboration with MD Anderson Cancer Center will launch advanced trials for the groundbreaking sarcoma treatment this year.

Founded by CEO Sigal Kalmanson Cusnir and her brother Ronen in 2019, Starget Pharma operates from Ness Ziona, Israel, with 20 employees and expanding US operations.

The funding will accelerate human clinical entries planned for 2026, enhance US manufacturing, and develop more candidates for breast and prostate cancers.

"This Series A financing marks a pivotal milestone for Starget, enabling us to scale our AI-driven discovery and establish US infrastructure," said CEO Sigal Kalmanson Cusnir.

This investment not only advances precision oncology but also boosts Louisiana's life sciences ecosystem, promising economic and clinical impacts worldwide.

Learn more at the Starget Pharma website.